Gap May Exist for Therapies for Age-related Diseases
The elderly is the fastest-growing segment of the global population, but only a few of their treatments have been clinically tested in age-appropriate patients
The elderly is the fastest-growing segment of the global population, but only a few of their treatments have been clinically tested in age-appropriate patients, and many therapies are still not available in suitable formulations and dosages, according to a report by GBI Research.
Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis, which significantly increases the risk of adverse drug events and hospitalization, with up to one third of elderly emergency admissions being drug-related, note the report (Geriatric Medicine Development - Carving Out New Opportunities to Treat Age-Related Diseases).
Pre-marketing drug trials often exclude geriatric patients and approved doses are not likely to be appropriate for the elderly, making off-label prescriptions relatively common for older patients. Antipsychotic medications, for example, are regularly prescribed off-label in up to 80% of care-home patients, to manage delirium, agitation and psychosis resulting from Alzheimer’s disease and schizophrenia, and these drugs have been associated with an increased risk of diabetes, cerebrovascular events and death, according to the authors.
The development of age-appropriate formulations and doses could allow for smarter prescriptions of approved drugs, such as anti-coagulants, anti-diabetic agents, antipsychotics and analgesics in older people, they note. Additionally, opportunities exist for companies to develop medicines for age-related diseases, including cognitive impairment, sarcopenia and neurodegenerative diseases.
Read the full release here.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
